Table 1 Main baseline characteristics of HCV monoinfected and HIV-HCV coinfected patients (n = 86)

Gender ratio (M/F)

2.0

6.7

0.063

Age (years)

50 (23–74)

46 (35–60)

0.066

Body weight (kg)

75 (41–130)

69 (52–96)

0.032

Men body weight (kg)

79 (44–130)

69 (52–96)

0.008

Body mass index (BMI)

25.7 (16.4-43.3)

22.1 (17.6-32.8)

0.003

Men body mass index (BMI)

25.8 (18.4-43.3)

22.2 (17.6-32.8)

0.002

Creatinine (μmol/L)

76 (49–189)

82 (45–123)

0.164

Cockroft clearance (mL/min)

105.7 (44–257.7)

90.2 (67.2-202.9)

0.244

MDRD (mL/min)

90.9 (34.2-167.5)

89.5 (58.2-144.7)

0.880

ALT (IU/mL)

62 (20–383)

60.5 (20–1492)

0.853

AST (IU/mL)

47 (20–402)

57 (26–969)

0.485

HCV RNA (log IU/mL)

6.1 (3.59-6.99)

6.4 (2.81-7.39)

0.111

Hemoglobin level (g/dl)

14.5 (8.2-17.2)

15.2 (12.1-18.8)

0.036

Men hemoglobin level (g/dl)

15 (8.3-17.2)

15.2 (12.1-18.8)

0.239

HCV genotype n (%)

0.566

1

48 (76)

14 (61)

2

2 (3)

1 (4)

3

6 (10)

4 (17)

4

7 (11)

4 (17)

Fibrosis score (Metavir) n (%)

0.780

0 – 2

29 (46)

12 (52)

3 – 4

34 (54)

11 (48)

HCV treatment status at baseline n (%)

0.434

HCV treatment naive

19 (30)

9 (41)

Nonresponders

25 (40)

9 (41)

Relapsers

19 (30)

4 (18)